Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
| ▸ | THRA | P10827 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ME2 | P23368 | 1/20 | 0.43 |
| ▸ | ME1 | P48163 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020118 | 0.88 | NPC1 (0.48) | S1PR1MAPTSMN1; SMN2THRBTHRA | |
| SCHEMBL11964525 | 0.88 | S1PR1 (0.56) | S1PR1MAPTSMN1; SMN2THRBTHRA | |
| SCHEMBL12125136 | 0.88 | S1PR1 (0.56) | S1PR1MAPTSMN1; SMN2THRBTHRA | |
| SCHEMBL9571636 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL8375690 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL8357893 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL9342490 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL9016853 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL9341873 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 | |
| SCHEMBL8380722 | 0.83 | THRB (0.64) | MAPTSMN1; SMN2THRBTHRANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | claimed |
| EP-3268375-B1 | PHOTOCHROMIC THIENOCHROMENE COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2022-06-15 | — | — | EP | claimed |
| EP-3071576-B9 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | claimed |
| CN-110730778-A | Photochromic indeno-fused phenanthropyran compounds | 光学转变有限公司 | 2020-01-24 | — | — | CN | claimed |
| CN-105838349-B | photochromic compounds | 光学转变公司 | 2019-12-06 | — | — | CN | claimed |
| EP-2652552-B9 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-02-17 | — | — | EP | claimed |
| EP-2652552-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-9051332-B1 | Photochromic indeno-fused ring pyran compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-06-09 | — | — | US | claimed |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | claimed |
| US-9029565-B1 | Fused ring indeno compounds for preparation of photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | claimed |
| US-20050004361-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL LIMITED (IE) | 2005-01-06 | — | — | US | claimed |
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| EP-2718755-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2360224-A1 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | S1PR1 3439/4885MAPT 1822/4885SMN1; SMN2 4769/4885 |
| US-20050004361-A1 | Thermally reversible; absorption ratio greater than 2.3 | CCND1, CCND3, CCND2 | S1PR1 4146/4885MAPT 4150/4885SMN1; SMN2 1502/4885 |
| US-20110129678-A1 | Photochromic compounds and compositions | CRY2, CRY1, PPOX | S1PR1 3071/4885MAPT 573/4885SMN1; SMN2 4030/4885 |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | INF2, INCENP, RB1 | S1PR1 4425/4885MAPT 2708/4885SMN1; SMN2 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.